Ozempic (semaglutide), Wegovy (semaglutide), Mounjaro (tirzepatide), and Zepbound (tirzepatide) have not been shown safe to combine with cannabis by the studies discussed here. Research about cannabis use disorder is different from research testing whether a particular THC or CBD product interacts with a prescription medicine.
The absence of a cannabis-specific warning in a drug label is not proof that the combination is harmless. Tell your prescriber or pharmacist about cannabis, including edibles, vaping products, oils, and CBD sold without a prescription.
Two studies that answer different questions
Semaglutide and cannabis use disorder diagnoses
A 2024 retrospective study by Wang and colleagues used electronic health records from 85,223 people with obesity and a separate population of 596,045 people with type 2 diabetes. Researchers compared semaglutide with non-GLP-1 medicines and followed recorded cannabis use disorder diagnoses for 12 months.
In the obesity population, semaglutide was associated with lower risk of a first recorded diagnosis (hazard ratio 0.56, 95% confidence interval 0.42–0.75) and a recurrent diagnosis (0.62, 0.46–0.84). These are relative associations, not the percentage of people who stopped cannabis.
The diabetes population also showed a lower estimate for a first diagnosis. However, its recurrent-diagnosis estimate was 0.66 with a confidence interval of 0.42–1.03. Because that interval includes 1, the result was not statistically conclusive. An earlier version of this page incorrectly described every diabetes finding as statistically significant.
Health records do not reliably measure how much cannabis a person uses, product potency, or whether prescribed medication was taken. Matching can reduce measured differences between groups but cannot remove all confounding. The study does not prove that semaglutide treats addiction or that combining it with cannabis is safe.
Cannabis and the body's natural GLP-1
A randomized laboratory study published in 2020 involved 20 cannabis users in a crossover comparison of oral, smoked, vaporized cannabis, and placebo. Researchers found lower circulating GLP-1 concentrations under cannabis conditions.
This was a small, short-term hormone study, not a trial of people taking GLP-1 medicines. It was not new 2024 or 2026 research. Natural hormone concentrations cannot tell us whether cannabis reduces semaglutide's clinical effects, changes an injected dose's absorption, or requires a larger prescription dose.
| Evidence | What it can support | What it cannot establish |
|---|---|---|
| Retrospective health records | An association between prescriptions and recorded diagnoses | A proven treatment for cannabis use disorder or combination safety |
| Small crossover hormone study | Short-term changes in measured hormones under study conditions | Weight-loss outcomes while taking a GLP-1 medicine |
| Medication labels and public-health guidance | Known risks of each product separately | A quantified risk for every cannabis and GLP-1 combination |
| Online personal reports | Questions worth raising with a clinician | Typical outcomes, a safe dose, or proof of an interaction |
Appetite and medication effectiveness
THC can increase appetite, but individual experiences do not establish how it changes long-term treatment outcomes. If appetite or eating patterns change, note the timing and discuss it at follow-up. Do not use a smaller appetite, fewer cravings, or more nausea as a reason to change a prescribed GLP-1 dose.
The Ozempic label and Zepbound label warn that delayed stomach emptying can affect absorption of oral medicines. Injected treatment does not pass through the stomach for absorption, but that does not eliminate concerns about other swallowed products. Oral GLP-1 formulations have their own administration and interaction requirements; do not assume all products behave like injections.
There is no validated timing interval that makes cannabis and GLP-1 treatment safe together. For prescription interactions, see our interaction guide, then ask a pharmacist to review your exact products.
Nausea, vomiting, and dehydration
GLP-1 medicines commonly cause gastrointestinal symptoms. Cannabis can also cause nausea and vomiting, including cannabinoid hyperemesis syndrome with repeated use. It should not be assumed to be a safe remedy for medication-related nausea.
Seek prompt medical assessment for repeated vomiting, severe or persistent abdominal pain, inability to keep fluids down, fainting, or very little urine. These symptoms can have several causes, including pancreatitis, gallbladder problems, dehydration, or cannabis-related illness. A clinician needs the full history to distinguish them.
Dry mouth alone does not measure dehydration. If you have kidney or heart disease, ask about appropriate fluids rather than adding electrolyte supplements automatically. Our nausea guide covers symptoms to discuss with the prescriber.
Edibles, impairment, and glucose monitoring
The CDC warns that edibles have delayed and sometimes prolonged effects. Taking more because an effect is not yet noticeable can cause poisoning. GLP-1-related delayed stomach emptying adds uncertainty, but the studies cited here do not establish an exact extra delay or a safe redosing schedule.
Cannabis can impair judgment, coordination, and reaction time. Do not drive or operate machinery while impaired. If you have diabetes, impairment may make it harder to recognize or respond to symptoms. GLP-1 treatment with insulin or a sulfonylurea carries greater low-glucose risk; follow the glucose-monitoring and treatment plan your clinician provides instead of assuming dizziness is only a cannabis effect.
Tell your care team about palpitations, worsening dizziness, constipation, or difficulty eating. These symptoms do not prove an interaction, but their timing can help the team assess the cause. Inform the anesthesia team about both GLP-1 medicines and cannabis before a procedure.
Keep cannabis products locked away from children and pets. For a suspected poisoning in the United States, contact Poison Control at 1-800-222-1222. Call emergency services for trouble breathing, a seizure, loss of consciousness, or other severe symptoms.
CBD is not an interaction-free alternative
CBD differs from THC, but lack of intoxication does not establish safety. NIH LiverTox describes medication interactions and liver-enzyme elevations, particularly at higher CBD doses. Nonprescription products can also vary in composition.
Do not assume a CBD oil is safer with your prescription than a THC-containing product. Bring the ingredient list, labeled strength, and other medications to a pharmacist. Product-specific review matters, especially when other medicines have liver, sedation, or interaction risks.
What to bring to a clinical review
Record the cannabis product and route, how often you use it, the labeled THC/CBD content if known, and whether symptoms follow cannabis use, an injection, or a recent medication change. Include alcohol, sleep medicines, supplements, and nonprescription products.
If you want to reduce or stop cannabis, say so directly. Ask about evidence-based behavioral treatment or addiction-care referral rather than relying on an incidental change in cravings. Semaglutide is not FDA-approved for cannabis use disorder, and the observational findings do not justify starting or increasing it for that purpose.
Cannabis rules vary by jurisdiction and can change. Check official local and destination rules before traveling; a medical authorization in one place does not establish permission elsewhere.
This article is educational, not a recommendation to combine substances or a substitute for medical advice.
